Indegene Ltd (NSE: INDGN) and Tarsons Products Limited (NSE: TARSONS) are both listed in the Life Sciences Tools and Services industry. Indegene has a market capitalisation of ₹14,921 Cr and Tarsons Products ₹1,537 Cr, as of 9 Nov 2026. Their P/E ratios are 37.3 and 107.4 respectively. Return on equity is 13.94% for Indegene and 2.26% for Tarsons Products. Over one year, Indegene's share price is up 14.6% and Tarsons Products's is up 9.3%.
| Metric | Indegene | Tarsons Products |
|---|---|---|
| NSE Symbol | INDGN | TARSONS |
| BSE Code | 544172 | 543399 |
| Share Price | ₹614.50 | ₹316.00 |
| Market Cap | ₹14,921 Cr | ₹1,537 Cr |
| P/E Ratio | 37.3 | 107.4 |
| Return on Equity | 13.94% | 2.26% |
| Return on Assets | 7.82% | 0.94% |
| Dividend Yield | 0.36% | 0.00% |
| Beta (1Y) | 0.45 | 0.76 |
| 1-Year Price Change | +14.6% | +9.3% |
| 3-Month Price Change | +8.0% | +0.8% |
| 52-Week Range | ₹414.00 – ₹638.00 | ₹164.45 – ₹375.00 |
| Latest Quarter | Q2 FY27 | Q1 FY27 |
| Quarterly Revenue | ₹1,122 Cr | ₹110 Cr |
| Quarterly Net Profit | ₹112 Cr | ₹-1 Cr |
| Net Margin | 10.0% | -1.3% |
| EPS (Basic, Quarter) | ₹4.67 | ₹-0.27 |
| Results Basis | consolidated | consolidated |
| Headquarters | Bengaluru, Karnataka | Kolkata, West Bengal |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, tech…
Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers bottles and carboys; boxes and racks; cell cell culture ware, centrifuge ware, clamps and stands, cryoware, desiccator, tubings and connectors, filtration, genomics and PCR consumables, laboratory equipment and utilities, liquid handling consumables and reusables, magnetic stirrer bar, pp storage plates, sampling aids, vials and tubes, and volumetric reusables. It also provides general lab ware products. Its products are used in molecular biology, cell cultur…
Indegene has a market capitalisation of ₹14,921 Cr, against ₹1,537 Cr for Tarsons Products as of 9 Nov 2026, about 9.7 times the size by market cap.
Indegene has a P/E of 37.3 and Tarsons Products a P/E of 107.4 as of 9 Nov 2026.
Indegene has a return on equity of 13.94% and Tarsons Products 2.26%.
Indegene's share price is up 14.6% over one year and Tarsons Products's is up 9.3%.
Indegene reported revenue of ₹1,122 Cr and net profit of ₹112 Cr for Q2 FY27. Tarsons Products reported revenue of ₹110 Cr and net profit of ₹-1 Cr for Q1 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.